Diagnosis of sepsis was based on the International Consensus Criteria 1 . Inclusion criteria were adult patients (≥18 years) admitted to a High Dependency Unit or ICU with CAP or peritonitis. Diagnosis of CAP was defined as a febrile illness associated with cough, sputum production, breathlessness, leukocytosis and radiological features of pneumonia acquired in the community or within less than 2 days of hospital admission 2 . Exclusion criteria were: pregnancy, an advanced directive to withhold or withdraw life sustaining treatment, admission for palliative care only and immune-compromise. Specific data were recorded in the eCRF to allow calculation of APACHE II scores 3 . Microbiological investigations were performed according to local policies and practices. Investigators recorded microbiological findings, including the organism(s) isolated, the source of the organism and the use of serological methods in the eCRF. Death or survival was recorded at 28 days from ICU admission, ICU discharge, hospital discharge and 6 months from ICU admission.
Blood samples were collected in 10 ml EDTA blood tubes and stored at -20°C until extraction. DNA was extracted from whole blood in centres in London, Paris and Munich. In London and Munich, extraction was performed using a salting out procedure 4 .
In Paris, genomic DNA was extracted and purified from EDTA-stabilized whole blood samples using the MagNA Pure Compact Instrument with the MagNA Pure Compact DNA Isolation Kit for 1 ml volume (Roche, Mannheim, Germany) according to manufacturer recommendations. All GenOSept DNA samples underwent a strict quality check for concentration and integrity analyzed by agarose gel electrophoresis prior to genotyping. Some of the GAinS samples were extracted using Maxwell 16 Blood DNA Purification kits (Promega UK Ltd) with the Maxwell 16 instrument (Promega UK Ltd) at the Wellcome Trust Centre for Human Genetics, University of Oxford.
VASST
Caucasian patients were recruited between July 2001 and April 2006 as described before 5 . DNA was extracted from the buffy coat of discarded blood samples, collected for plasma analysis, using the QIAamp DNA maxi kit (Qiagen, Mississauga, ON, Canada) . The research ethics board at the coordinating centre (University of British Columbia) approved the genetic analysis (approval number, H02-50076). Written consent was obtained from all participants or their authorised representative.
PROWESS
Caucasian patients were recruited between July 1998 and June 2000 as described before 6, 7 . DNA was extracted from Whatman FTA TM blood spot cards, collected initially for analysis of the Factor V Leiden polymorphism. The ethics board at each study center approved the original trial protocol and written consent was obtained from all participants or their authorised representative. The Bioethics committees determined that no additional consent was necessary for further genetic studies on the anonymised samples.
Genome-wide genotyping and quality control
Genotyping of the GenOSept DNA collection was performed by one of the partners in the GenOSept Consortium (Munich, Germany) using the Affymetrix 5.0 SNP array. The additional GAinS sample set was genotyped using the Illumina Human OmniExpress Bead chip at the Wellcome Trust Centre for Human Genetics genotyping core facility, University of Oxford. The VASST and PROWESS sample sets were both genotyped using the Illumina Human 1M-Duo BeadChip array. Genotyping data of each cohort was cleaned in Oxford by removing poorly performing samples based on the following quality control (QC) criteria: call rate (<98%), extreme heterozygosity (>3 standard deviations from the mean), relatedness (PI_HAT (proportion identity by descent) > 0.2), population outliers (see example in Supplementary Figure 5) , and gender discrepancies. See Supplementary Table 2 for a summary of excluded individuals in each sample collection. Only individuals with lung or abdomen as a source of infection and the patients for whom 28-day outcome was known were included in the analysis -also the number of phenotype exclusions based on this criteria are shown in Supplementary Table 2 and Figure 1 .The following criteria were used to exclude unreliable SNPs: minor allele frequency (MAF) (<0.01), Hardy-Weinberg equilibrium (P<1x10 -10 ), and SNP call rate (<98% if MAF>0.05; <99% if MAF < 0.05). All these data cleaning steps were performed using PLINK 8 . After SNP QC, 354,483 (GenOSept), 644,775 (GAinS), 936,437 (VASST), and 934,810 (PROWESS) autosomal SNPs remained for imputation.
Imputation
The GWAS data sets (GenOSept, GAinS, VASST and PROWESS) were imputed separately by first pre-phasing the genotypes using SHAPEIT 9 before imputation using IMPUTE2
10
. The 1000 Genomes phase 1 (integrated January 2012) data version was used as a reference panel. Insertion deletion polymorphisms were removed; only SNPs were included in the analysis.
Statistical power
Statistical power to detect an association with 28-day survival from sepsis due to pneumonia with a conventional genome-wide significance p-value threshold of 5x10 -8 , varying odds ratios and minor allele frequencies, was calculated using R and is presented in Supplementary Figure 1 . To select the SNPs to be genotyped in the final cohort, we used a commonly used p-value threshold of < 1x10 -5 for suggestive evidence of association in the discovery cohort. Statistical power with this less stringent p-value threshold in the discovery cohorts is shown in Supplementary Figure 1d .
Statistical analyses of the genome-wide data sets
All imputed data sets were analysed separately using SNPTEST2 11 , taking into account the imputed genotype uncertainty (frequentist score test), and using age and the first four MDS components (generated in the QCd patient data exclusively; see Supplementary Figure 5b ) as covariates in logistic regression with the additive model of association. These covariates were included in the model as age is known to be a strong determinant of mortality and the first four MDS dimensions were found to form distinct groups when study individuals were labelled by country (Supplementary Figure 5b) . Because GenOSept and the additional GAinS discovery data sets were recruited using the same protocol, imputed genotypes were analysed together using SNPTEST2 before the meta-analysis.
The association results (OR and standard error) of each individual cohort were combined in a meta-analysis using PLINK. The more conservative random effects meta-analysis method was used instead of a fixed effects analysis as the latter tends to exaggerate p-values in the presence of heterogeneity 12 . Potentially unreliably imputed SNPs were filtered out based on minor allele frequency (<0.02), imputation info value from SNPTEST (< 0.8), and Hardy-Weinberg equilibrium (P< 1x10 -10 ). After these QC measures, 5,888,277 autosomal SNPs remained in the meta-analysis.
We performed a meta-analysis for 28-day survival in the predefined group of patients with sepsis originating from pneumonia (1553 individuals of whom 359 died).We also analysed the whole cohort of patients with sepsis originating from pneumonia or intra-abdominal infection (2534 individuals of whom 572 died within 28 days of ICU admission). The number of patients with intra-abdominal infections was too small for an adequately powered analysis. See Table 1 for the sample numbers in each individual cohort.
Additional genotyping and statistical analysis
Loci with P-values less than 1x10 -5 in the meta-analysis of either pneumonia only or pneumonia and intraabdominal infections combined, were genotyped using the Sequenom iPLEX MassArray system in the additional GAinS sample set of CAP and peritonitis sepsis patients combined (1002 patients of whom 174 died). Of these, 538 patients were diagnosed with CAP, of whom 106 patients died. Only SNPs with call rates> 90% and samples with call rates> 80% were included in the analysis. The additional set was analysed using PLINK with age as a covariate in logistic regression.
The most significant SNP after meta-analysis in patients with pneumonia, rs4957796, failed Sequenom genotyping and was therefore genotyped using High-Resolution Melting Curve Analysis (HRMA). PCR was performed with primers (Metabion) GGATGAGAGACTCAAATATCTATTGTT(F) and ATTATAGCCTCATTAGTTTAGAAATCCTAC(R). An unlabelled probe (Metabion) with a 3'-amino-C7 modification and sequence AATATCACATCATTGAAATTATTTGCTTTTAAGAA was used to improve genotyping resolution. Amplification was performed with an excess of the reverse primer and probe, to generate sufficient single-stranded product for the probe to anneal to. A 10μl reaction was used, containing 0.5μl 25ng/μl template DNA, 1μl 10x PCR buffer (Qiagen), 0.4μl 25mM MgCl2 (Qiagen), 1μl dNTP mix (Bioline; 2mM of each dNTP), 1μl LC-Green Plus (Idaho Technology), 0.06μl HotStarTaq DNA polymerase (Qiagen), 1μl primer/probe mix (0.5μM forward primer, 5μM reverse primer and 5μM probe) and 5μl water. PCR steps involved an initial step at 95°C for 10 minutes, followed by 56 cycles of 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 30 seconds. Samples were then kept at 72°C for 5 minutes before cooling. A final melting step at 95°C for 1 minute was performed before allowing samples to cool to room temperature. High resolution melting was performed using a LightScanner (Idaho Technology) and melting was done from 50°C to 98°C at 0.1°C/sec. Melt curves were analysed using LightScanner software Call-IT 2.0 using derivative normalised melting plots between 62°C and 72°C. 96 samples were also Sanger sequenced in the forward and reverse direction using primers GGTGACTTTCTATAGCGTCTTTAAC (F) and GCCTCATTAGTTTAGAAATCCTACTT (R). All genotypes were identical between HRMA and sequencing. An example of a melting curve plot used to determine the rs4957796 genotype is shown in Supplementary Figure 6 .
Because rs4957796 SNP was originally imputed, the discovery samples within the GenOSept cohort were subsequently directly genotyped using the HRMA method (we did not have access to the DNA samples collected within the VASST and PROWESS studies). Imputation concordance was calculated as the proportion of imputed genotypes that were consistent with direct genotyping. For this comparison the genotype with the highest probability was assigned as the imputed genotype. In the actual association analyses imputation probabilities rather than exact genotypes were used.
Time-to-event analysis
The follow-up of patients was continued for 6 months in GenOSept/GAinS, 3 months in VASST and 28 days in PROWESS. Cox regression models to evaluate the effect of genotype on survival time stratified by cohort and adjusted for age were performed using STATA v12. The proportionality of hazards was checked using the test on Schoenfeld residuals proposed by Grambsch and Therneau 13 . The survival analysis was repeated for time to death up to six months for GenOSept and GAinS cohorts. Owing to non-proportionality beyond 28-days, the 14 . Survival curves were created using R. Table 3 . Top associations (loci with P < 1x10 -5 ) after the genome-wide meta-analysis of 28-day survival among patients with sepsis caused by pneumonia (additive model). Results shown for GenOSept/GAinS (G), VASST (V), and PROWESS (P) discovery sets are based on imputed data (except where indicated), whereas the additional GAinS results are based on direct genotyping. Only the SNP with the most significant P-value per locus and those that were included in the additional GAinS genotyping are shown (more than one SNP per association peak was genotyped when possible). MAF=minor allele frequency; OR=odds ratio. SNPs highlighted in bold are those that show stronger evidence of association after adding the additional cohort in the combined analysis. NA denotes missing data. (* although p-value in the replication set is <0.05 the direction of the effect is in the opposite direction to that seen in the discovery set.) Table 4 . Top associations (loci with P < 1x10 -5 ) after the genome-wide meta-analysis of 28 day survival among patients with sepsis caused by pneumonia or abdominal infections (additive model). Results shown for GenOSept (G), VASST (V), and PROWESS (P) discovery sets are based on imputed data (except where indicated), whereas additional GAinS results are based on directly genotyped data. Only the SNP with the most significant P-value per locus and those that were included in the additional GAinS genotyping are shown (more than one SNP per association peak was genotyped when possible). MAF=minor allele frequency; OR=odds ratio. NA denotes missing data. 
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